Clopan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clopan

Property Description
Active ingredient Metoclopramide hydrochloride
Form Tablet, Oral Solution, Injection
Pharmacological class Antiemetic, Prokinetic Agent
General purpose Manages nausea, stops vomiting, and improves gut motility
Origin Synthetic, substituted benzamide class
Prescription Status Prescription-only (Rx-only)

What is Clopan and Its Core Ingredient?

Clopan is a prescription-only medicine containing the single active ingredient Metoclopramide hydrochloride, a compound chemically derived from the substituted benzamide class. The medicine is available across multiple pharmaceutical preparations for clinical use.

The core of the medicine is its synthetic origin, a factor that differentiates it from naturally derived compounds. This chemical structure is clinically recognized for its ability to selectively target and interact with key nervous system receptors, providing an evidence-based approach to managing upper gastrointestinal distress.

Clopan's Pharmacological Class and General Purpose

Clopan holds the distinct, dual classification of a Prokinetic Agent and an Antiemetic. Its primary general purpose is to provide relief by controlling the urge to vomit while simultaneously regulating the physical movement of the stomach and small intestine.

Its pharmacological action involves blocking dopamine receptors in the brain to reduce nausea and stimulating gut motility. This dual mechanism is the product's defining feature, supporting its use in managing symptoms where sluggish gut movement is a contributing factor to persistent discomfort.

Available Forms of Clopan

To accommodate diverse patient needs, Clopan is manufactured in several distinct pharmaceutical preparations. These preparations include the common oral tablet and the oral solution for ingestion, as well as a sterile injection solution intended for parenteral administration, such as via the intravenous (IV) or intramuscular (IM) routes in a clinical setting. This variety of forms ensures flexibility in delivering the therapeutic substance, particularly in acute or non-oral situations.

Regulatory References

  1. NIH Metoclopramide Overview
  2. Metoclopramide StatPearls Overview

What side effects are possible with Clopan?

Possible Side Effects and Safety Information

Clopan (Metoclopramide) carries an official safety profile defined by serious neurological risks, time-related constraints, and system-specific adverse reactions documented in regulatory sources (FDA, EMA, etc.).

Adverse Reaction Scope

Classification Examples of Documented Effects System-Organ Class Involved
Very Common Somnolence (sleepiness) Nervous System Disorders
Common Diarrhoea, Asthenia (general weakness) Gastrointestinal Disorders
Uncommon Bradycardia, Hyperprolactinaemia Cardiac Disorders, Endocrine Disorders
Frequency Not Known Tardive Dyskinesia, Neuroleptic Malignant Syndrome (NMS), Cardiac Arrest Nervous System Disorders, Cardiac Disorders

Serious Adverse Reactions: Official labeling highlights the risk of Tardive Dyskinesia (TD), a potentially irreversible movement disorder, which necessitates limiting treatment duration. Neuroleptic Malignant Syndrome (NMS), a potentially fatal condition characterized by hyperthermia and muscle rigidity, is also documented. Severe cardiovascular effects, including Cardiac Arrest and Severe Bradycardia, have been reported following intravenous administration.

Population-Specific Safety Considerations: The risk of Extrapyramidal Reactions is explicitly higher in children and young adults (under 30 years). Dose reduction is formally recommended for patients with renal impairment or severe hepatic impairment due to reduced clearance of the drug. The medication may also exacerbate symptoms in patients with underlying Parkinson's Disease.

Duration-Related Safety Patterns: Regulatory guidance mandates that treatment be generally limited to a short duration, such as 12 weeks or less, because the risk of Tardive Dyskinesia increases with the duration of exposure and the cumulative dose.

Safety-Related Limitations: Contraindications restrict use in patients with conditions like pheochromocytoma or a history of drug-induced TD. Intravenous administration requires injection as a slow bolus (over at least three minutes) to mitigate the risk of serious cardiovascular events.


Regulatory Safety Summary

The official safety information establishes that the medicine's risk profile is dominated by the potential for neurological adverse events, which are strongly linked to the duration of exposure. Frequency classification provides a clear, official description of the expected common effects, while explicit limitations on use define the constraints necessary to address documented serious systemic risks across different patient populations.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Metoclopramide (Clopan) overdose describes prominent central nervous system and neurological movement disorders. Documented clinical manifestations can include drowsiness, disorientation, confusion, seizures, and the occurrence of extrapyramidal reactions (EPS). Severe, life-threatening outcomes are officially documented in prescribing information, such as cardio-respiratory arrest and the hematological risk of Methemoglobinemia.

Mandated Emergency Action The primary regulatory requirement upon suspicion of overdose is to seek immediate medical attention and discontinue the medication. Urgent contact with emergency services is necessary if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Treatment is officially defined as symptomatic and supportive.

Overdose Management Note Official Regulatory Statement
Drug Removal Dialysis is not likely to be an effective method of drug removal.
Targeted Agents Anticholinergic drugs may be used for extrapyramidal reactions, and methylene blue is specified for Methemoglobinemia reversal.
Observation Extrapyramidal reactions are typically self-limiting, often resolving within 24 hours after drug discontinuation.

Population-Specific Considerations Overdose events in infants and children have included seizures and lethargy. The risk of Methemoglobinemia is specifically noted in premature and full-term neonates given high exposure.

Therapeutic Uses of Clopan

What Clopan Treats: Main Uses and Benefits

Clopan (Metoclopramide) is applied across domains where additional symptomatic support is needed, primarily focusing on conditions characterized by a combination of disruptive nausea, vomiting, and symptoms related to impaired gastrointestinal movement. The medication is intended to assist with easing symptoms that create noticeable physiological strain and interfere with daily comfort.

The core therapeutic relevance of this medicine includes symptomatic support for conditions such as symptomatic, documented Gastroesophageal Reflux Disease (GERD); treatment for diabetic gastroparesis (diabetic gastric stasis) in adults; and reducing the occurrence and managing the discomfort of sickness associated with emetogenic cancer chemotherapy or postoperative care.

This medicine is generally used to help manage severe episodes where symptoms become temporarily overwhelming. It contributes to easing the overall symptom load, particularly when patients experience discomfort from delayed digestion or persistent sickness.

“This medication is applied in clinical settings that involve acute or unstable symptom patterns, offering supportive relief when symptoms interfere with routine activities.”


Quick Fact: Relief for Impaired Digestion Clopan may assist with supporting the digestive process in the stomach, which helps address symptom clusters related to delayed gastric emptying, such as persistent nausea, vomiting, and abdominal fullness.

Regulatory References

  1. DailyMed official labeling information

Eligibility and Restrictions for Use

Clopan (Metoclopramide) eligibility is strictly defined by regulatory guidelines concerning a patient’s pre-existing conditions and population demographics. Use is absolutely contraindicated in several groups due to officially documented risks.

Contraindicated Populations

Regulatory labels prohibit use for patients with a known history of Gastrointestinal Hemorrhage, Mechanical Obstruction, or Perforation, as the medicine stimulates gut motility. It is also prohibited for patients with Pheochromocytoma, Epilepsy or a history of seizures, and those with Parkinson's disease or a history of Tardive Dyskinesia.

Age and Organ Function Restrictions

The medicine is contraindicated in children under 1 year of age. For pediatric patients (ages 1 to 18), the safety and effectiveness for general use have not been established by some authorities. Older adult patients may require conditional use, often involving a lower starting dosage.

Use is restricted in patients with moderate or severe renal impairment or severe hepatic impairment; official regulatory documents mandate a dose reduction to prevent drug accumulation. Furthermore, treatment for non-acute conditions is strictly limited to a duration of 12 weeks.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Clopan (metoclopramide) based on documented pharmacokinetic and pharmacodynamic patterns.

Formal Regulatory Prohibitions

Co-administration is formally contraindicated with Dopaminergic Agonists (such as Levodopa) due to mutual pharmacological antagonism. The combination with other medicinal products likely to cause Extrapyramidal Reactions (EPS), including many antipsychotics, is prohibited due to the heightened risk of developing severe neurological disorders. Use with Monoamine Oxidase Inhibitors (MAOIs) is advised against by regulatory documents due to the documented risk of hypertension.

Pharmacokinetic and Exposure Alterations

The clearance of Clopan is linked to metabolism by the CYP2D6 enzyme. Co-administration with strong CYP2D6 inhibitors (e.g., Fluoxetine, Paroxetine) increases metoclopramide plasma concentration, a pharmacokinetic interaction that necessitates a mandatory dosage reduction. Due to the product’s effect on gut motility, the systemic absorption of other medicines can be altered; it is documented to decrease Digoxin bioavailability and increase Cyclosporine bioavailability, requiring careful monitoring of these drug concentrations.

Pharmacodynamic Synergism and Constraints

Additive effects are noted with central nervous system (CNS) depressants, including alcohol, opioids, and sedatives, due to the increased potential for sedation and other CNS effects. A regulatory constraint specifies a minimum interval of at least 6 hours between administrations. Furthermore, dose adjustments are required in specific patient populations, such as those with renal impairment or severe hepatic impairment, to prevent drug accumulation and mitigate interaction severity stemming from reduced clearance.

Mechanism of Action

How Clopan Works: Mechanism of Action

Clopan functions as a direct inhibitor of the Calpain (CAPN) family of cysteine proteases, specifically mu-calpain and m-calpain, whose activity is dependent on intracellular calcium levels. This interaction blocks the enzyme's catalytic site, thereby interrupting the molecular step of pathological protein cleavage.

By preventing Calpain-mediated proteolysis, Clopan maintains the structural integrity of cells, particularly in the nervous system. This mechanistic effect stabilizes the neuronal cytoskeleton and critical signaling molecules, thereby modulating the cellular response to stress and excitotoxicity.

Clopan's action modulates the downstream physiological cascade that is linked to cell death (apoptosis and necrosis) and cellular inflammatory processes. This focused intervention attenuates the overall impact of dysregulated calcium signaling and pathological proteolysis, leading to a reduced rate of cellular degradation and the attenuation of injury-related cellular responses.

Dosage and Administration Information

How Clopan is Used

Clopan (metoclopramide) administration follows specific instructions detailing the route, dosage, timing, and duration of therapy. This medicine is prescribed as an oral tablet, oral solution, or a sterile solution for intravenous (IV) and intramuscular (IM) injection.


Administration Guidelines

Domain Standard Administration
Route of Administration Oral (Tablet, Solution), Intravenous (IV), and Intramuscular (IM) injection.
Standard Adult Dosing Typically 10 mg per dose, with maximum daily doses varying by indication (e.g., 60 mg maximum for GERD, 30 mg maximum for acute antiemetic use).
Timing and Frequency Oral doses are administered 30 minutes before each meal and at bedtime. The dose is typically repeated up to four times daily.
Minimum Dosing Interval A minimal interval of at least 6 hours must be respected between any two consecutive administrations.

Use Patterns and Adjustments

Clopan use is strictly time-limited. For acute conditions, such as established nausea and vomiting, the maximum recommended treatment course is 5 days. For chronic gastrointestinal disorders like GERD, the maximum duration is typically 4 to 12 weeks, as prolonged use is generally not advised beyond these periods.

Dose Adjustment for Impairment: Dose modification is necessary for patients with reduced organ function. For individuals with moderate-to-severe renal or hepatic impairment, the initial dose should generally be reduced by 50% to prevent drug accumulation.

Recent Clinical Evidence

Research Evidence and Overview of Studies for Clopan (Metoclopramide)


Evidence from Clinical Trials for Diabetic Gastroparesis

Research has explored how symptoms change over time in diabetic gastroparesis, a condition marked by delayed emptying of the stomach. The evidence primarily stems from short-term Randomized Controlled Trials (RCTs), which were observed in adult populations with documented diabetic gastric stasis. These studies examined patient-reported outcomes describing perceived discomfort, such as nausea, vomiting, abdominal fullness, and early satiety.

In addition to symptom scores, the research also monitored the rate of gastric emptying. The research highlights that the reported patient symptoms were not consistently associated with the objective measurement of accelerated gastric emptying. There is limited information for long-term outcomes or how durable the observed patterns might be beyond the typically short trial window of 4 to 12 weeks.


Research in Symptomatic Gastroesophageal Reflux Disease (GERD)

Studies for GERD was evaluated in research involving adults with conditions characterized by fluctuating or episodic manifestations, particularly when conventional treatments were insufficient. Research examined outcomes related to physical discomfort, focusing on the frequency and intensity of heartburn and regurgitation. Evidence suggests certainty remains low due to evidence quality that varies across studies, and the focus on a specific subgroup of patients with persistent symptoms.


Studies in Chemotherapy-Induced and Postoperative Sickness

The drug was studied for its application in two distinct scenarios: Chemotherapy-Induced Nausea and Vomiting (CINV) and Postoperative Nausea and Vomiting (PONV). For CINV, high-dose Intravenous RCTs examined outcomes capturing phases of heightened symptom activity, measuring the rate of sickness episodes during the acute phase (first 24 hours). Research describes that its use for PONV was associated with measurements of a lower incidence of PONV compared to placebo in some studies, typically monitored in the immediate hours following surgery.


What is Still Uncertain in the Research Landscape

Research highlights that the patient-reported experience was observed to have an imperfect link to the objective measure of gastric emptying speed. Furthermore, comparative evidence is often lacking as the drug is frequently studied for short-term changes as one component within a multi-drug antiemetic strategy. For use in infants and children, official reviews indicate that data for certain groups remain insufficient, with evidence characterized by small sample sizes.

Key Studies & References Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Health Professional Version (Context for CINV regimens)

Frequently Asked Questions (FAQ)

Common questions about Clopan (FAQ)


Q: Can Clopan be used for sleep issues?

A: Regulatory documents describe the medicine's use for conditions like diabetic gastroparesis and gastroesophageal reflux. While official adverse reaction lists note that somnolence (sleepiness) is a common side effect, the medicine is not officially indicated or approved for the treatment of primary sleep issues.


Q: Is feeling tired a normal side effect of Clopan?

A: According to official product information, effects like feeling tired, asthenia (general weakness), and somnolence (sleepiness) are classified as common to very common side effects. This means these effects have been reported by a measurable percentage of patients in official safety summaries.


Q: How long do the side effects of Clopan usually last?

A: Regulatory information indicates that certain effects, such as nervousness or headache experienced when discontinuing the medicine, have been reported to generally subside. However, regulatory guidance mandates that treatment duration must be limited because the risk of the serious neurological movement disorder Tardive Dyskinesia increases with the length of time the medicine is used.


Q: Can Clopan cause stomach problems?

A: Yes, official adverse reaction reports include effects on the gastrointestinal system. Diarrhea, for example, is classified as a common effect, meaning it has been reported in a measurable percentage of patients during studies.


Q: What happens if I miss a scheduled time to take Clopan?

A: Official guidance typically states that if a dose is forgotten, it should be skipped entirely. Official guidance specifies that the next scheduled dose is typically taken at the correct time, adhering to the minimal required interval of at least six hours between administrations.


Q: What should I expect in the first week of taking Clopan?

A: Official prescribing information notes that relief of nausea and vomiting may begin early in treatment. However, regulatory warnings indicate that neurological movement disorders, known as Extrapyramidal Symptoms (EPS), can also occur within the first two days of starting the medicine.


Q: What is known about Clopan use during pregnancy?

A: The medicine is classified as Pregnancy Category B in the US regulatory system. Official reviews of the available data generally do not show a significant association between the medicine's use during pregnancy and an increased risk of major birth defects or fetal death.


Q: What is the difference between Clopan and its generic name?

A: The active substance in the medicine is officially known as metoclopramide hydrochloride, which is its generic name. Clopan is the brand name under which a manufacturer may choose to market the product. Generic versions are required to meet the same quality and effectiveness standards as the brand-name product.


Q: What happens if I accidentally take two Clopan doses?

A: Official guidance states that a single extra dose is not expected to be harmful, but taking higher amounts beyond the prescribed amount increases the risk of serious effects. Overdosage symptoms may include severe drowsiness, disorientation, and uncontrolled muscle movements.


Q: Is Clopan available over the counter?

A: No, official regulatory labeling, such as that provided by the FDA, designates the medicine as a prescription-only drug (Rx only).


Q: Is it possible to have an allergic reaction to Clopan?

A: Official regulatory summaries indicate that severe allergic reactions are possible. The documented signs of such a reaction may include hives, swelling of the face, lips, tongue, or throat, and difficulty breathing.


Q: Can I take Clopan with over-the-counter cold medicine?

A: Official drug interaction warnings indicate caution when taking the medicine with other central nervous system (CNS) depressants, such as certain pain relievers, opioids, or sedatives. Some cold medicines may contain ingredients that also cause sedation, which could lead to additive effects and increase the potential for drowsiness.


Q: What other medicines interact with Clopan?

A: Regulatory documents list several classes of drugs known to interact. These include dopaminergic agonists, medicines that inhibit the CYP2D6 enzyme, and central nervous system (CNS) depressants. Specific pharmacokinetic interactions, such as altered blood levels of Digoxin and Cyclosporine, are also documented.


Q: Is it safe to take Clopan with vitamin supplements?

A: Official patient guidance emphasizes the importance of informing a healthcare provider about all substances being taken. This includes prescription, over-the-counter drugs, and all vitamin or herbal supplements. This is necessary to identify and prevent potential interactions as described in product labeling.


Q: How fast does Clopan start working?

A: The speed of action depends on the route of administration, as defined in official pharmacokinetic information. It is stated to begin working in 1 to 3 minutes following an intravenous dose, 10 to 15 minutes after intramuscular injection, and 30 to 60 minutes after taking an oral dose.


Q: Is Clopan appropriate for people with a history of heart problems?

A: Official regulatory warnings include caution when administering the medicine to patients with, or at risk for, fluid overload, such as those with congestive heart failure. Severe cardiovascular effects, including severe bradycardia and cardiac arrest, are documented risks related to the drug's use.


Q: Is Clopan approved by the FDA?

A: Yes, the drug substance, metoclopramide hydrochloride, and its initial brand-name formulation received US approval from the FDA prior to 1982.


Q: Is Clopan addictive or habit-forming?

A: Official regulatory warnings focus heavily on the risk of movement disorders, specifically Tardive Dyskinesia, which is linked to the duration of exposure. The official labeling does not include specific warnings or statements related to addiction or habit-forming potential.


Q: How is Clopan eliminated from the body?

A: Official pharmacokinetic information indicates that the primary route of elimination is through the kidneys. Approximately 85% of the administered dose is officially reported to appear in the urine within 72 hours.


Q: Why is Clopan sometimes called by a different name?

A: The medicine can be referred to by its active ingredient, metoclopramide hydrochloride, as well as by its brand name, such as Clopan (or Reglan in some regions). Brand names can differ based on the specific country or manufacturer.


Q: Does Clopan have a risk evaluation and mitigation strategy (REMS)?

A: Yes, the FDA required a Risk Evaluation and Mitigation Strategy (REMS) for metoclopramide-containing tablets and orally disintegrating tablets in 2009. The purpose of the REMS is to help manage the risk of the serious neurological disorder, Tardive Dyskinesia, by including a mandatory Medication Guide for patients.


Q: What is the active ingredient in Clopan?

A: The active ingredient in the medicine is officially identified in regulatory documents as metoclopramide hydrochloride.

How should Clopan be stored and disposed of?

How to Store and Dispose of Clopan? (Metoclopramide)

The storage and disposal of Clopan must strictly follow regulatory guidance to ensure stability and safety.

Storage Requirements

Clopan is required to be stored at Room Temperature, which means keeping the medication away from excess heat and moisture. It must be kept in the original container and the lid must be tightly closed to protect it from light and environmental exposure. For child safety, the product must be stored out of the reach and sight of children, and safety caps must always be secured.

Disposal Instructions

Official disposal requires the use of a drug take-back program or an authorized collection site. If these are unavailable, the medicine may be mixed with an undesirable substance, sealed in a container, and discarded in the household trash according to the regulated procedure. Clopan must not be thrown into drains or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clopan found in:

A-Z Index: